OPTH ▲ +4.9% - Optimi Health Corp. $OPTH - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Optimi Health rose 4.9% following news that the company is expanding its clinical program with a Phase 3 trial evaluating MDMA-assisted therapy for post-traumatic stress disorder. The advancement to late-stage clinical testing represents a significant milestone in the company's drug development pipeline and signals progress toward potential regulatory approval and commercialization. 16-SEP-2026 08:25 AM ET